NASDAQ:OCX OncoCyte Q2 2024 Earnings Report $3.44 +0.05 (+1.47%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$3.44 +0.00 (+0.12%) As of 04/25/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast OncoCyte EPS ResultsActual EPS-$0.36Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncoCyte Revenue ResultsActual Revenue$0.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncoCyte Announcement DetailsQuarterQ2 2024Date8/8/2024TimeN/AConference Call DateThursday, August 8, 2024Conference Call Time5:00PM ETUpcoming EarningsOncoCyte's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Thursday, May 8, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by OncoCyte Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 8, 2024 ShareLink copied to clipboard.There are 7 speakers on the call. Operator00:00:00Thank you for standing by. My name is Rochelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Operator00:00:37I would now like to turn the call over to Jeff Ramsden from PCG Advisory. Please go ahead. Speaker 100:00:45Thank you, Rachelle, and thank you to everyone for joining us for today's conference call to discuss Aquasight's Q2 2024 financial results and recent operating highlights. If you've not seen today's shareholder letter, please visit investors. Aquacyte.com to read it. Today's prepared remarks build upon the information already shared in this robust letter. Before turning the call over to OncoCyte President and CEO, Josh Riggs, I'd like to go over our Safe Harbor statement. Speaker 100:01:13The company will make projections and forward looking statements regarding future events. Any statements that are not historical facts are forward looking statements. These statements are made pursuant to and within the meaning of the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's Forms 10 ks and 10 Q, which identify risks that may cause future actual results or events to differ materially. OncoCyte expressly disclaims any intent or obligation to update these forward looking statements, except as otherwise may be required under applicable law. Speaker 100:01:50Finally, we'll be taking questions today on the line from our covering analysts as well as written questions from our investor community. I'd like to now turn the call over to Josh Riggs. Speaker 200:02:01Thanks, Jeff. Welcome and thank you for tuning in. We have on the call with us today our Chief Science Officer, Doctor. Eki Schutz as well as Chief Financial Officer, Andrea James. It's great to be able to announce the successful commercial launch of GraftAssure with our initial beta customers. Speaker 200:02:22We had confidence going into launch, but you never really know until your product is out in the field. And the feedback that we're getting is exceeding our expectations. As we started our pivot last year, we said we were going to do 3 things: going to keep our cash burn low, produce a product and welcome a channel strategic partner. And we've done all 3 and we are thrilled with the partnership and investment from Bio Rad. Those three pillars set us beautifully set us up beautifully to meet the commitment made earlier this year to launch our Graft Assure research product in Q2, which we are happy to say that we met. Speaker 200:02:59Going forward, we expect to maintain a capitalized business model, focus on-site adoption in the U. S. And Germany and deliver an IVD product to the market. Success in all three sets us up to disrupt the transplant testing market and deliver exceptional margins. Our Head of Commercial and I have been out in the field talking with customers and exploring more partnerships. Speaker 200:03:21It's just like a flower that keeps opening up, the more we engage with the market, the more it's responding. We believe that over the next few years, our research product will double or triple the amount of research done using donor derived cell free DNA. This biomarker has been clinically accepted and is nearly standard of care and yet you don't see an explosive growth in research. We believe this is reflective of how the central lab model, which we aim to disrupt, has not been able to fully support the research community and all the questions that they want to ask. We know that there are a lot of these questions that are going unanswered today. Speaker 200:04:00Putting a research tool out there in the field and giving research institutions around the world access to it meets a real market need. One of our early adopters is studying pediatric transplant patients. And sadly, there's a paucity of research in this space and seeing one of our first centers jump in feels really good. Empowering research not only serves the market more broadly, but it also creates new opportunities for OncoCyte, including in pharmaceutical research use. You can see the early innings of that with the Phase 2 clinical trial by Hi Bio, which used our Vitagraph kidney assay to monitor for responses to their anti CD38 therapy, the results of which were published in the New England Journal of Medicine. Speaker 200:04:48Since then, a second publication has shown the ability to monitor for response to a second anti CD38 therapy for antibody mediated rejection. In this case series study, patients were given daratumumab off label to treat antibody mediated rejection and Vitagraph Kidney was able to identify that the drug was working with a simple blood test. In addition to these publications, you may have seen in the shareholder letter that in the second quarter, we signed an agreement to be the provider of and research partner of choice. Before I go on, there's an important real world human element here to consider regarding the partnership with pharma. Many kidney transplant recipients experience antibody mediated rejection. Speaker 200:05:46And when that happens, historically, there are not a lot of options for doctors or the patient. They may lose the organ or go back on dialysis or even eventually die. And it's a serious problem. And we're humbled by the opportunity to support pharmaceutical companies as they study ways to solve that problem and turn organ rejection from a potential death sentence into a manageable condition. Of course, detecting antibody mediated rejection very early, which data has shown that our technology can do, will be very important to solving this problem once drugs are available that can treat the disease. Speaker 200:06:24Even though we are a small company and we are still largely pre revenue and transplant, we sit upon an established body of science and more than 10 years of research in the field. We have long been out in front with the clinical data that we are generating. We're excited as you saw in the shareholder letter that for the first time on July 11th, researchers outside of OncoCyte began using our commercial research technology, GraftAssure. And it's a major effort for labs like this to bring up the workflow. It's a significant investment of time and resources and they don't take it lightly. Speaker 200:07:02They are signing up because they believe in what we are building. We believe that these labs are exhausted by the send out only model and that they want to work with us in building an IVD technology. They wanted IVD test so that they can detect transplant rejection quickly and easily on-site and they want to be able to run that test alongside all routine tests. They like us believe in the power of democratized access to technology. In our launch program, they start with some sample product to get comfortable using the assay before switching over to revenue producing product. Speaker 200:07:39As we pointed out in the shareholder letter, we are about 6 weeks into the commercial launch of GraptoSure and we have transplant centers that represent nearly 25% of the U. S. Transplant volume in our funnel and roughly the same percentage in Germany, our 2 key launch markets. This is exceptional and much faster than we would have expected with an RUO product. The market enthusiasm for GraftAssure has given us the confidence to make some incremental investments in the back half of the year to support commercial launch and the FDA submission process for the IVD product. Speaker 200:08:20These investments include FDA compliant software engineering necessary to generate a test result, consumables to support the FDA submission as well as an inventory build to bring customer sites up. We aim to hold our cash burn in Q3 and Q4 relatively in line with what you saw in Q2. Our product development team expects to deliver a completed data package to the FDA by summer next year And depending on how quickly the FDA is processing submissions at that time, the earliest we could expect a positive coverage decision is in late Q4. We enjoy bench strength to support us in the IVD process, which is why I have invited Ekki to the call. He is here to help address any questions you might have today on the details of the FDA approval process. Speaker 200:09:11It's going to be a lot of fun in the next couple of years. We have a lot to execute, but we are dedicated to democratizing access to novel molecular diagnostic testing, improving patient outcomes and creating substantial shareholder value along the way. Now I'd like to introduce a newcomer to our earnings call. We welcomed Andrea James to OncoCyte in June and she has hit the ground running. Some of you may know Andrea from Tesla or Axon. Speaker 200:09:41I'm thrilled to work with Andrea and we are already benefiting so much from our insights, particularly when it comes to building and preparing for explosive growth. She is delivering decisive analytical leadership and heterodox thinking to our team and I'm delighted by the partnership. I've asked her to tell you why she came to OncoCyte. I think it was a great achievement for us to be able to attract her and I think she sees in Aquacyte what we think the world will see over time. And as some of you know, Andrea has a history of being ahead of the curve. Speaker 200:10:14Andrea? Speaker 300:10:15Thank you, Josh. Hi, everyone. It's great to be here. And some of you may know me from Axon or Tesla or the sell side before that. As Josh said, I joined OncoCyte to help build and scale the company. Speaker 300:10:28There were 4 primary factors that drew me to OncoCyte: mission, timing, strategy and team. First, the mission here is attractive, and it reminds me of what we had at Axon, which is to save lives. You'll notice in the new investor presentation we published today that we synthesized our mission very succinctly as follows: to democratize access to novel molecular diagnostic testing to improve patient outcomes. We have an opportunity to do a lot of good with our technology and to do it quite soon, which brings me to timing. Where we are in our commercialization journey was very attractive to me. Speaker 300:11:09When I started talking with the company this spring, I learned that OncoCyte was just on the cusp of commercializing a product with more than a decade of history of development behind it. My background is in tech and finance. I don't have a background in health care. And I wasn't interested in going to a company where it would take 10 years to bring a product to market. So thank you to those of you on the call who have worked for 10 years on this product. Speaker 300:11:32In addition to timing, I found the strategy to be highly compelling. I'm very much attracted to the strategy of selling diagnostic tests at software like gross margins via a business model that is disruptive to the industry. We have the potential to be an asset like high margin company that can scale quickly and eventually become quite large. The analyst and the investor in me has always appreciated businesses like that And my guess is that many of you do too. 3rd, I was drawn to the quality of the team. Speaker 300:12:07We enjoy having world renowned scientists in this company, including our Chief Science Officer, Doctor. Ecki Schutz, who is on the line today. These scientists have extensive experience developing cell free DNA products, developing immuno oncology products and with obtaining regulatory approval to sell diagnostic margins. Josh Riggs, who is sitting here beside me in Irvine, California, is a deep subject matter expert. He exhibits a clear ability to make important decisions with a high degree of clarity. Speaker 300:12:48The company's pivot over the past few years has not been easy, and I admire the combination of smarts, integrity and grit. It also helps to be a CFO stepping into a culture that already enjoys strong financial discipline. Of course, it was born of necessity, but I knew that this could be a great partnership. That muscle of fiscal discipline will remain strong and it will support future operating leverage. Okay. Speaker 300:13:17So the strategy makes sense and the team punches above their weight. Now the question is, how will this strategy play out? I saw 3 things that point to a company that is potentially in the early innings of success. First, we have great indications of product market fit. The interest we are already gaining with GraftAssure is pretty exciting. Speaker 300:13:42What's amazing is that research centers are proactively reaching out to OncoCyte to get access to the transplant diagnostic even without forward sales reach from us. And wouldn't it be great if we can invest more in that sales muscle and go faster? 2nd, the strategic investment and partnership with Bio Rad really, really is a big deal. This company's channel partner is also its 2nd largest investor. And third, the scientific validation has many proof points, the most recent of which appeared in the May 2024 publication of the New England Journal of Medicine. Speaker 300:14:17It was clear to me that OncoCyte is focusing on a scalable, high margin product that builds a clear market need and is selling it into prebuilt channels. This adds up to the potential to be a big winner. Now to be clear, I also came in with eyes wide open. While I knew some of the investors in the company and I was aware of their strong support and while I was impressed with the management team and the Board, it is also true that we are a tiny company, our trading volume is still small and we have a weak balance sheet. All of this is solvable. Speaker 300:14:53What was also clear to me from my prior background is that investors will provide money to companies with certain characteristics. These characteristics include the ability to move fast and capture opportunities, the ability to manage risks and retire them and a compelling value proposition in the customer market. And this is where we are. The opportunity over the next 2 to 3 years is very large. In the near term, we have the opportunity to capture market share by selling a known biomarker test into the transplant diagnostic market. Speaker 300:15:27We also have a compelling opportunity over the 5 to 10 year period, which is a period I've always focused on with companies such as Tesla or Axon. Over that time frame, it is not unreasonable that we could become a $1,000,000,000 company. That potential is why I am here. We have a compelling story to tell, and I'm eager to help tell it as well as guide it. As far as telling that story, you can see that with this earnings report, we are introducing a shareholder letter. Speaker 300:15:54We are also publishing a new investor deck that explains why we are investing in molecular diagnostic testing and specifically in developing test kits versus developing an in house clinical lab model. In these materials, we presented a graphic that is intended to help you understand why we are so excited about our beta customers that we are bringing up online as we speak. In the graphic, we show a projected revenue build that assumes we get FDA approval to sell an IVD product in late 2025 and assumes that the customer transplant center eventually switches from sending out their clinical tests to managing their patient populations in house. Now there's a reason why we do a forward looking statement disclaimer on all projections, and that is because there are no guarantees. But we also felt that it was important to share our view of what we are building from where we sit today. Speaker 300:16:44You can count on us to be transparent on our growth journey, And that includes transparency not only about the opportunities, but also about the risks. As for the numbers we reported in the quarter, they're in the shareholder letter and you don't need me to read off of tables for you. The one thing I would highlight is that our April fundraise was very successful. We had participation from new and existing investors, including our first corporate partner Bio Rad, and it was done at market with no warrant coverage and no discounts. This speaks to the fact that we have a real market opportunity to go after and that others in the capital markets are starting to see that opportunity. Speaker 300:17:20I'd also highlight that with the preferred stock redemptions in April, we now enjoy a streamlined capital structure with just common stock and no debt or preferred stock, which hopefully excites you as much as it does me as we hit an inflection point. We truly value our partnership and relationship with the investment community, including our analysts and shareholders, so Day by day, our path to revenue is steadily being derisked. Day by day, our path to revenue is steadily being derisked. Once we are capturing that revenue, we think you'll be pleased with the leverage in the business model itself, which is both high gross margin and capital light. Okay. Speaker 300:18:01So now we welcome your questions. Go ahead, Jeff. Do we have any questions in the queue? Speaker 100:18:08We do. Michelle, can you allow the verbal questions? Operator00:18:17Certainly. Your first question is from Mike Matson with Needham. Please ask your question. Speaker 400:18:42Hey, everyone. How's it going today? This is Joseph on for Mike. Speaker 200:18:46That's good, Mike. Thanks. Speaker 400:18:50Yes, this is Joseph on for Mike. But just quick question on Vitagraph started out. I saw in the press release that you talked about increasing throughput at the CLIA lab. Just kind of want to get an understanding of where this test stands. I assume volume hasn't started yet, but maybe you could dissect that a little bit. Speaker 400:19:10Maybe this prep work, what are you kind of aiming for volume for this test? And then obviously liver is still under review at CMS. So if you could give an update there, that would be helpful. Speaker 200:19:22Yes. Thanks for the question. I think what we've done is expanded our capacity in the lab in Nashville. So we're talking about an investment that we're making into that lab infrastructure. It's primarily to support the extra work that's coming at us for the FDA program. Speaker 200:19:41So that's just about the amount of samples, the amount of data that we need to generate to support the FDA submission. So that's really more of a capital spend to support that effort. We've largely pulled back on most of our commercial efforts towards the LDT service product and put all of that energy into working on the site placements where we just kind of had an overwhelming response and needed to pivot our commercial team more towards activating sites for the RUO product. Speaker 400:20:13Okay. Yes, that makes sense. So I guess maybe just to ask another question on that. As we look at the chart, I guess you provided for the beta path. In terms of just material revenue before that inflection point, I guess estimated inflection point around second half twenty twenty six, Is there anything that we should start baking into our estimates or is the next really material driver IBD, Vitagraph for kidney? Speaker 200:20:43Yes. With the low burn, every dollar of revenue feels material to us. But with the RUO product, I mean, it's going to be modest revenue. And it's hard for us to gauge that because this is a new product for the industry. They haven't had anything like this. Speaker 200:21:01So we could be pleasantly surprised by the orders, but I think we're going to keep those expectations modest for now until we get confidence that it's going to be much above. And I think we do a good job in that graphic kind of highlighting that there's a relatively slow burn of revenue per site for the RUO product. And then as you pointed out, it really kicks up once we have an IVD product out there. Speaker 400:21:27Okay. And then maybe just final question just as we look forward to these next couple of years. In terms of site adoption and cash burn, I'm just kind of wondering how you're level setting that. If you're more looking at just finding the strategic centers and planting relationships there or if it's going to be a slow buildup of customers there over time? Speaker 200:21:53Thanks. I would say one advantage that we have in transplant is an exceptional concentration at the top. Transplant is a relatively complicated surgery and so it tends to aggregate at near the higher end academic centers. That's both here in the U. S. Speaker 200:22:12And Europe and around the world. And so any one of these top 100 centers feels meaningful to us because the top 100 here in the United States do 80% of the transplant volume or better. And so I guess if I'm going to answer your question, when we get to 10 to 15 to 20 sites, we will have picked up a very meaningful percentage of that local market opportunity. I think that's what we're excited about. So when we look at our funnel today, I mean, 25% of the U. Speaker 200:22:46S. Transplant volume is represented there. And so, I mean, all of these guys feel strategic to us. Speaker 400:22:54Okay, great. Yes, that's all super helpful. Thank you very much for taking our questions Speaker 100:22:59today. Sure. Operator00:23:03Your next question comes from the line of Mark Massaro with BTIG. Your line is open. Speaker 500:23:11Hey guys. This is Vivian on for Mark. Thanks for taking the questions. So as it relates to FDA approval, could you just remind us of any interim milestones? What publications and studies you're expecting to leverage to get there? Speaker 500:23:25I think in the press release, the Q sub was mentioned. And then I believe FDA clearance in late 2025 sort of represents your bull case. But just can you give us a range of the timing of that? Speaker 200:23:40Sure. I'll take some of the timing question and then I'll ask Ekki to talk about the milestones that he has in front of him. I think we I think we're as you might guess, we're very hopeful that the FDA will move quickly and we don't really control that process. But we're going to give ourselves the best chance we have to get through by the end of 'twenty five. That may drift into early part of 'twenty six, just depending on how quickly the FDA is processing things at that time. Speaker 200:24:06But, Eki, if you could, just talk a little bit about the key milestones that you have in front of us, Qsub and then what you guys are doing from a product development point of view and where you hope to be kind of going into next year? Speaker 600:24:21All right. Thank you, Josh. So our QSAT is planned like that's in 6 to 8 weeks from now. We are right now putting all the material together. I would say we are 50% there. Speaker 600:24:34We are going to start, I would say, the revision process next week. So we are all going into that and revise it by all the needs. And it's a pretty formalized process, where you are just presenting your intended use, you're presenting the method or the assay. And you are presenting what kinds of studies like analytical validation, clinical validation you're planning. And then you ask the FDA question, are you fine with that? Speaker 600:25:16Is our analytical validation recording what you are looking for is our clinical validation recording what you are looking for. And then we hope to get good answers. We had made actually pretty good experience with the FDA when we did our BDD submission last year. They are very cooperative. And so they are really trying to work with you and not against you, which I really appreciated. Speaker 600:25:50So bottom line that there is some time to tell us, okay, this is okay, this might be perhaps this or that detail, something where we want to have a modification, which at the end of the day helps us for the design and planning of our IVD endeavor. That said, also the IVD route is a very, very formalized way of putting documents and data together. It starts with Phase 1, which is design spending and inputs. So you are completely put together how your design should look like and have all the inputs in there like, okay, what are we going to achieve? What is our target? Speaker 600:26:47And that's something we want to get finalized by in actually 6 weeks from now. So we want to have that phase done in 6 weeks. And from there, you are getting into the 2nd phase, which is development and design output. So from there, you are developing everything like work packages, what you want to do, how you want to do that, which study and so forth. And then the design output, it means you are controlling that what you have put into your design document really can be achieved. Speaker 600:27:26So that's the second so called phase gate. And then the 3rd phase is verification and validation. That's where we are going to do an analytical validation and physical validation with the at that point locked in final product. And this we are have planned to get accomplished by Q4 20 fivetwenty 26. So that's the entire plan. Speaker 600:27:59It's a lot of writing documents and just show the FDA that you are have thought about everything that needed to be thought about and that you are not just getting some data randomly put together by chance. The entire idea behind that is starting with the so called design control. Everything needs to be set from the very beginning and then you are just working along what you have planned. Speaker 200:28:33Perfect. Understood. Thank you, Aki. Operator00:28:36And then I Speaker 200:28:37just want to make one comment on I just want to make one quick comment. Just one quick comment. Yes. One thing that we've been pleasantly surprised with is kind of the warm reception to the IVD program we felt from the community. One of the questions we're asking these sites as we're bringing them up and we're moving them through the funnel is, hey, are you interested in participating in the IVD program? Speaker 200:28:59And it's just kind of been overwhelmingly positive. I think these centers want to help us get the samples together. They want to help us with the reproducibility studies. And so it's really feeling like a community effort here to push the IVD process along. So I think we're overwhelmed by the positive support that we're getting from the community. Speaker 200:29:21And I think there's just a general excitement that they're going to have access to this technology, and they get to help make it happen. Operator00:29:31There are no further questions from the line at this time. I'd like to ask Jeff to see if we have any questions from the webcast. Speaker 100:29:41Yes, we do have a few actually. Thank you. Josh, Andrea, how do you calculate the $1,000,000,000 transplant testing market opportunity? And how does OncoCyte plan to capture its $1,000,000,000 market opportunity? Speaker 200:29:57I mean, it's a good question. I think we put this out, I think, in our investor deck. But we've got an estimate of somewhere around 3,000,000 to 3,500,000 testing opportunities globally. And that number, we're obviously multiplying that by a mix of our RUO product and our IVD product, where we expect to be IVD in the U. S. Speaker 200:30:18And Europe and then probably say RUO Rest of World. That market is growing, at least according to current estimates about 9% a year. So we see the $1,000,000,000 as a relatively conservative estimate of what the market opportunity is. And we're not going to move that up until we have a chance to do more price discovery. And so it's just something that's hard to do until, let's say, you actually have the IVD product out there and know what you're going to get reimbursed. Speaker 200:30:46So we're erring on the side of being conservative there. From a market capture point of view, I think we've talked about this a good bit, but it's democratization, right? It's giving people access, and it's meeting the demand where it is, which, you know, right now, the demand is at the local center, and they don't have access to a technology that works for them today. Speaker 300:31:11Do you want to add just a little bit about that $1,000,000,000 total addressable market is based on the current clinical indication? Speaker 200:31:20Yes. I mean, I think the most exciting thing for us that's come out of the past 2 or 3 months is the work that's being done on like the anti CD38 drugs where they're really meeting an unmet clinical need from a pharma point of view. And that just opens up kind of just these significant monitoring opportunities. So therapeutic efficacy monitoring, like is the drug working, then also recurrence monitoring. And we're seeing a lot of this in oncology right now. Speaker 200:31:53And there's just an enormous amount of value creation that's happening in the oncology space, just kind of like on that therapeutic efficacy and recurrence monitoring. And we're starting to see that emerge here in transplant. And so we're we've got our fingers crossed that these trials will continue to be successful, so that patients have an option instead of just losing their organ. And I think that creates that's an incredible tailwind for us because we're out in front there. And so I would say that easily expands the market opportunity that's in front of us. Speaker 400:32:33Very good. Speaker 600:32:36If I may, I would just add to what TOS was saying to make it really clear what the new situation that we have created is. I recall a net board meeting like perhaps 8 months ago, where we were talking how much would you use the test in a high risk population. And most of the people are saying, why should I? We don't have any therapy. Why do I want to know? Speaker 600:33:04And this has dramatically changed. Now we have the first working therapy for chronic active antibody mediated rejection. And it's not only something where we can show our test is perfect monitoring. It's also a huge, huge relief for patients who are suffering, Because earlier than that, there was no therapeutic option. And the organ would ultimately be lost, and now we have a therapeutic option. Speaker 600:33:37And our contribution is really to show that people are going into this disease earlier, then we can do it with standard of care. And Speaker 200:34:00Great. Thank you, Akhi. Speaker 100:34:04I have one other question, Josh. Speaker 200:34:07Okay. Speaker 100:34:07How does OncoCyte envision building recurring revenue streams when most diagnostics currently are performed episodically. That wasn't even as bad as before. Sorry. Speaker 200:34:20Yes. I would say the transplant is inherently a recurring revenue opportunity because patients are living with their organs hopefully for 10, 12, 15 years or better. And unfortunately though, there's a high rate of rejection. And so there's just inherently a number of touch points over the life of the patient. The physician just needs a non invasive way or a minimally invasive way to check on that organ. Speaker 200:34:56And we along with the other players in the space are kind of meeting that need. And so I think it's just inherent to the product and the industry that we're in. Speaker 100:35:11Got it. Okay, great. There's no more questions. Rochelle? Operator00:35:18Currently, we don't have any questions from the line. Speaker 300:35:32Thanks, Rachelle and Jeff. I guess we'll give it maybe like 5 seconds here, pregnant applause, and then maybe Josh will close this out. Speaker 200:35:44Okay, guys. Thanks everybody for joining us today. I mean, we're obviously excited about where we're at as a company. It feels great to be out in the field with the product engaging with the research community and just feeling a groundswell of support. So we look forward to updating you guys on our progress and capturing these sites across the United States and across Europe. Speaker 200:36:09We'll have some very exciting things to announce here in the future and thanks for playing along. Operator00:36:16Thank you. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallOncoCyte Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) OncoCyte Earnings HeadlinesOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIElon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.April 26, 2025 | Brownstone Research (Ad)OncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comSee More OncoCyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OncoCyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OncoCyte and other key companies, straight to your email. Email Address About OncoCyteOncoCyte (NASDAQ:OCX), a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.View OncoCyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 7 speakers on the call. Operator00:00:00Thank you for standing by. My name is Rochelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Operator00:00:37I would now like to turn the call over to Jeff Ramsden from PCG Advisory. Please go ahead. Speaker 100:00:45Thank you, Rachelle, and thank you to everyone for joining us for today's conference call to discuss Aquasight's Q2 2024 financial results and recent operating highlights. If you've not seen today's shareholder letter, please visit investors. Aquacyte.com to read it. Today's prepared remarks build upon the information already shared in this robust letter. Before turning the call over to OncoCyte President and CEO, Josh Riggs, I'd like to go over our Safe Harbor statement. Speaker 100:01:13The company will make projections and forward looking statements regarding future events. Any statements that are not historical facts are forward looking statements. These statements are made pursuant to and within the meaning of the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's Forms 10 ks and 10 Q, which identify risks that may cause future actual results or events to differ materially. OncoCyte expressly disclaims any intent or obligation to update these forward looking statements, except as otherwise may be required under applicable law. Speaker 100:01:50Finally, we'll be taking questions today on the line from our covering analysts as well as written questions from our investor community. I'd like to now turn the call over to Josh Riggs. Speaker 200:02:01Thanks, Jeff. Welcome and thank you for tuning in. We have on the call with us today our Chief Science Officer, Doctor. Eki Schutz as well as Chief Financial Officer, Andrea James. It's great to be able to announce the successful commercial launch of GraftAssure with our initial beta customers. Speaker 200:02:22We had confidence going into launch, but you never really know until your product is out in the field. And the feedback that we're getting is exceeding our expectations. As we started our pivot last year, we said we were going to do 3 things: going to keep our cash burn low, produce a product and welcome a channel strategic partner. And we've done all 3 and we are thrilled with the partnership and investment from Bio Rad. Those three pillars set us beautifully set us up beautifully to meet the commitment made earlier this year to launch our Graft Assure research product in Q2, which we are happy to say that we met. Speaker 200:02:59Going forward, we expect to maintain a capitalized business model, focus on-site adoption in the U. S. And Germany and deliver an IVD product to the market. Success in all three sets us up to disrupt the transplant testing market and deliver exceptional margins. Our Head of Commercial and I have been out in the field talking with customers and exploring more partnerships. Speaker 200:03:21It's just like a flower that keeps opening up, the more we engage with the market, the more it's responding. We believe that over the next few years, our research product will double or triple the amount of research done using donor derived cell free DNA. This biomarker has been clinically accepted and is nearly standard of care and yet you don't see an explosive growth in research. We believe this is reflective of how the central lab model, which we aim to disrupt, has not been able to fully support the research community and all the questions that they want to ask. We know that there are a lot of these questions that are going unanswered today. Speaker 200:04:00Putting a research tool out there in the field and giving research institutions around the world access to it meets a real market need. One of our early adopters is studying pediatric transplant patients. And sadly, there's a paucity of research in this space and seeing one of our first centers jump in feels really good. Empowering research not only serves the market more broadly, but it also creates new opportunities for OncoCyte, including in pharmaceutical research use. You can see the early innings of that with the Phase 2 clinical trial by Hi Bio, which used our Vitagraph kidney assay to monitor for responses to their anti CD38 therapy, the results of which were published in the New England Journal of Medicine. Speaker 200:04:48Since then, a second publication has shown the ability to monitor for response to a second anti CD38 therapy for antibody mediated rejection. In this case series study, patients were given daratumumab off label to treat antibody mediated rejection and Vitagraph Kidney was able to identify that the drug was working with a simple blood test. In addition to these publications, you may have seen in the shareholder letter that in the second quarter, we signed an agreement to be the provider of and research partner of choice. Before I go on, there's an important real world human element here to consider regarding the partnership with pharma. Many kidney transplant recipients experience antibody mediated rejection. Speaker 200:05:46And when that happens, historically, there are not a lot of options for doctors or the patient. They may lose the organ or go back on dialysis or even eventually die. And it's a serious problem. And we're humbled by the opportunity to support pharmaceutical companies as they study ways to solve that problem and turn organ rejection from a potential death sentence into a manageable condition. Of course, detecting antibody mediated rejection very early, which data has shown that our technology can do, will be very important to solving this problem once drugs are available that can treat the disease. Speaker 200:06:24Even though we are a small company and we are still largely pre revenue and transplant, we sit upon an established body of science and more than 10 years of research in the field. We have long been out in front with the clinical data that we are generating. We're excited as you saw in the shareholder letter that for the first time on July 11th, researchers outside of OncoCyte began using our commercial research technology, GraftAssure. And it's a major effort for labs like this to bring up the workflow. It's a significant investment of time and resources and they don't take it lightly. Speaker 200:07:02They are signing up because they believe in what we are building. We believe that these labs are exhausted by the send out only model and that they want to work with us in building an IVD technology. They wanted IVD test so that they can detect transplant rejection quickly and easily on-site and they want to be able to run that test alongside all routine tests. They like us believe in the power of democratized access to technology. In our launch program, they start with some sample product to get comfortable using the assay before switching over to revenue producing product. Speaker 200:07:39As we pointed out in the shareholder letter, we are about 6 weeks into the commercial launch of GraptoSure and we have transplant centers that represent nearly 25% of the U. S. Transplant volume in our funnel and roughly the same percentage in Germany, our 2 key launch markets. This is exceptional and much faster than we would have expected with an RUO product. The market enthusiasm for GraftAssure has given us the confidence to make some incremental investments in the back half of the year to support commercial launch and the FDA submission process for the IVD product. Speaker 200:08:20These investments include FDA compliant software engineering necessary to generate a test result, consumables to support the FDA submission as well as an inventory build to bring customer sites up. We aim to hold our cash burn in Q3 and Q4 relatively in line with what you saw in Q2. Our product development team expects to deliver a completed data package to the FDA by summer next year And depending on how quickly the FDA is processing submissions at that time, the earliest we could expect a positive coverage decision is in late Q4. We enjoy bench strength to support us in the IVD process, which is why I have invited Ekki to the call. He is here to help address any questions you might have today on the details of the FDA approval process. Speaker 200:09:11It's going to be a lot of fun in the next couple of years. We have a lot to execute, but we are dedicated to democratizing access to novel molecular diagnostic testing, improving patient outcomes and creating substantial shareholder value along the way. Now I'd like to introduce a newcomer to our earnings call. We welcomed Andrea James to OncoCyte in June and she has hit the ground running. Some of you may know Andrea from Tesla or Axon. Speaker 200:09:41I'm thrilled to work with Andrea and we are already benefiting so much from our insights, particularly when it comes to building and preparing for explosive growth. She is delivering decisive analytical leadership and heterodox thinking to our team and I'm delighted by the partnership. I've asked her to tell you why she came to OncoCyte. I think it was a great achievement for us to be able to attract her and I think she sees in Aquacyte what we think the world will see over time. And as some of you know, Andrea has a history of being ahead of the curve. Speaker 200:10:14Andrea? Speaker 300:10:15Thank you, Josh. Hi, everyone. It's great to be here. And some of you may know me from Axon or Tesla or the sell side before that. As Josh said, I joined OncoCyte to help build and scale the company. Speaker 300:10:28There were 4 primary factors that drew me to OncoCyte: mission, timing, strategy and team. First, the mission here is attractive, and it reminds me of what we had at Axon, which is to save lives. You'll notice in the new investor presentation we published today that we synthesized our mission very succinctly as follows: to democratize access to novel molecular diagnostic testing to improve patient outcomes. We have an opportunity to do a lot of good with our technology and to do it quite soon, which brings me to timing. Where we are in our commercialization journey was very attractive to me. Speaker 300:11:09When I started talking with the company this spring, I learned that OncoCyte was just on the cusp of commercializing a product with more than a decade of history of development behind it. My background is in tech and finance. I don't have a background in health care. And I wasn't interested in going to a company where it would take 10 years to bring a product to market. So thank you to those of you on the call who have worked for 10 years on this product. Speaker 300:11:32In addition to timing, I found the strategy to be highly compelling. I'm very much attracted to the strategy of selling diagnostic tests at software like gross margins via a business model that is disruptive to the industry. We have the potential to be an asset like high margin company that can scale quickly and eventually become quite large. The analyst and the investor in me has always appreciated businesses like that And my guess is that many of you do too. 3rd, I was drawn to the quality of the team. Speaker 300:12:07We enjoy having world renowned scientists in this company, including our Chief Science Officer, Doctor. Ecki Schutz, who is on the line today. These scientists have extensive experience developing cell free DNA products, developing immuno oncology products and with obtaining regulatory approval to sell diagnostic margins. Josh Riggs, who is sitting here beside me in Irvine, California, is a deep subject matter expert. He exhibits a clear ability to make important decisions with a high degree of clarity. Speaker 300:12:48The company's pivot over the past few years has not been easy, and I admire the combination of smarts, integrity and grit. It also helps to be a CFO stepping into a culture that already enjoys strong financial discipline. Of course, it was born of necessity, but I knew that this could be a great partnership. That muscle of fiscal discipline will remain strong and it will support future operating leverage. Okay. Speaker 300:13:17So the strategy makes sense and the team punches above their weight. Now the question is, how will this strategy play out? I saw 3 things that point to a company that is potentially in the early innings of success. First, we have great indications of product market fit. The interest we are already gaining with GraftAssure is pretty exciting. Speaker 300:13:42What's amazing is that research centers are proactively reaching out to OncoCyte to get access to the transplant diagnostic even without forward sales reach from us. And wouldn't it be great if we can invest more in that sales muscle and go faster? 2nd, the strategic investment and partnership with Bio Rad really, really is a big deal. This company's channel partner is also its 2nd largest investor. And third, the scientific validation has many proof points, the most recent of which appeared in the May 2024 publication of the New England Journal of Medicine. Speaker 300:14:17It was clear to me that OncoCyte is focusing on a scalable, high margin product that builds a clear market need and is selling it into prebuilt channels. This adds up to the potential to be a big winner. Now to be clear, I also came in with eyes wide open. While I knew some of the investors in the company and I was aware of their strong support and while I was impressed with the management team and the Board, it is also true that we are a tiny company, our trading volume is still small and we have a weak balance sheet. All of this is solvable. Speaker 300:14:53What was also clear to me from my prior background is that investors will provide money to companies with certain characteristics. These characteristics include the ability to move fast and capture opportunities, the ability to manage risks and retire them and a compelling value proposition in the customer market. And this is where we are. The opportunity over the next 2 to 3 years is very large. In the near term, we have the opportunity to capture market share by selling a known biomarker test into the transplant diagnostic market. Speaker 300:15:27We also have a compelling opportunity over the 5 to 10 year period, which is a period I've always focused on with companies such as Tesla or Axon. Over that time frame, it is not unreasonable that we could become a $1,000,000,000 company. That potential is why I am here. We have a compelling story to tell, and I'm eager to help tell it as well as guide it. As far as telling that story, you can see that with this earnings report, we are introducing a shareholder letter. Speaker 300:15:54We are also publishing a new investor deck that explains why we are investing in molecular diagnostic testing and specifically in developing test kits versus developing an in house clinical lab model. In these materials, we presented a graphic that is intended to help you understand why we are so excited about our beta customers that we are bringing up online as we speak. In the graphic, we show a projected revenue build that assumes we get FDA approval to sell an IVD product in late 2025 and assumes that the customer transplant center eventually switches from sending out their clinical tests to managing their patient populations in house. Now there's a reason why we do a forward looking statement disclaimer on all projections, and that is because there are no guarantees. But we also felt that it was important to share our view of what we are building from where we sit today. Speaker 300:16:44You can count on us to be transparent on our growth journey, And that includes transparency not only about the opportunities, but also about the risks. As for the numbers we reported in the quarter, they're in the shareholder letter and you don't need me to read off of tables for you. The one thing I would highlight is that our April fundraise was very successful. We had participation from new and existing investors, including our first corporate partner Bio Rad, and it was done at market with no warrant coverage and no discounts. This speaks to the fact that we have a real market opportunity to go after and that others in the capital markets are starting to see that opportunity. Speaker 300:17:20I'd also highlight that with the preferred stock redemptions in April, we now enjoy a streamlined capital structure with just common stock and no debt or preferred stock, which hopefully excites you as much as it does me as we hit an inflection point. We truly value our partnership and relationship with the investment community, including our analysts and shareholders, so Day by day, our path to revenue is steadily being derisked. Day by day, our path to revenue is steadily being derisked. Once we are capturing that revenue, we think you'll be pleased with the leverage in the business model itself, which is both high gross margin and capital light. Okay. Speaker 300:18:01So now we welcome your questions. Go ahead, Jeff. Do we have any questions in the queue? Speaker 100:18:08We do. Michelle, can you allow the verbal questions? Operator00:18:17Certainly. Your first question is from Mike Matson with Needham. Please ask your question. Speaker 400:18:42Hey, everyone. How's it going today? This is Joseph on for Mike. Speaker 200:18:46That's good, Mike. Thanks. Speaker 400:18:50Yes, this is Joseph on for Mike. But just quick question on Vitagraph started out. I saw in the press release that you talked about increasing throughput at the CLIA lab. Just kind of want to get an understanding of where this test stands. I assume volume hasn't started yet, but maybe you could dissect that a little bit. Speaker 400:19:10Maybe this prep work, what are you kind of aiming for volume for this test? And then obviously liver is still under review at CMS. So if you could give an update there, that would be helpful. Speaker 200:19:22Yes. Thanks for the question. I think what we've done is expanded our capacity in the lab in Nashville. So we're talking about an investment that we're making into that lab infrastructure. It's primarily to support the extra work that's coming at us for the FDA program. Speaker 200:19:41So that's just about the amount of samples, the amount of data that we need to generate to support the FDA submission. So that's really more of a capital spend to support that effort. We've largely pulled back on most of our commercial efforts towards the LDT service product and put all of that energy into working on the site placements where we just kind of had an overwhelming response and needed to pivot our commercial team more towards activating sites for the RUO product. Speaker 400:20:13Okay. Yes, that makes sense. So I guess maybe just to ask another question on that. As we look at the chart, I guess you provided for the beta path. In terms of just material revenue before that inflection point, I guess estimated inflection point around second half twenty twenty six, Is there anything that we should start baking into our estimates or is the next really material driver IBD, Vitagraph for kidney? Speaker 200:20:43Yes. With the low burn, every dollar of revenue feels material to us. But with the RUO product, I mean, it's going to be modest revenue. And it's hard for us to gauge that because this is a new product for the industry. They haven't had anything like this. Speaker 200:21:01So we could be pleasantly surprised by the orders, but I think we're going to keep those expectations modest for now until we get confidence that it's going to be much above. And I think we do a good job in that graphic kind of highlighting that there's a relatively slow burn of revenue per site for the RUO product. And then as you pointed out, it really kicks up once we have an IVD product out there. Speaker 400:21:27Okay. And then maybe just final question just as we look forward to these next couple of years. In terms of site adoption and cash burn, I'm just kind of wondering how you're level setting that. If you're more looking at just finding the strategic centers and planting relationships there or if it's going to be a slow buildup of customers there over time? Speaker 200:21:53Thanks. I would say one advantage that we have in transplant is an exceptional concentration at the top. Transplant is a relatively complicated surgery and so it tends to aggregate at near the higher end academic centers. That's both here in the U. S. Speaker 200:22:12And Europe and around the world. And so any one of these top 100 centers feels meaningful to us because the top 100 here in the United States do 80% of the transplant volume or better. And so I guess if I'm going to answer your question, when we get to 10 to 15 to 20 sites, we will have picked up a very meaningful percentage of that local market opportunity. I think that's what we're excited about. So when we look at our funnel today, I mean, 25% of the U. Speaker 200:22:46S. Transplant volume is represented there. And so, I mean, all of these guys feel strategic to us. Speaker 400:22:54Okay, great. Yes, that's all super helpful. Thank you very much for taking our questions Speaker 100:22:59today. Sure. Operator00:23:03Your next question comes from the line of Mark Massaro with BTIG. Your line is open. Speaker 500:23:11Hey guys. This is Vivian on for Mark. Thanks for taking the questions. So as it relates to FDA approval, could you just remind us of any interim milestones? What publications and studies you're expecting to leverage to get there? Speaker 500:23:25I think in the press release, the Q sub was mentioned. And then I believe FDA clearance in late 2025 sort of represents your bull case. But just can you give us a range of the timing of that? Speaker 200:23:40Sure. I'll take some of the timing question and then I'll ask Ekki to talk about the milestones that he has in front of him. I think we I think we're as you might guess, we're very hopeful that the FDA will move quickly and we don't really control that process. But we're going to give ourselves the best chance we have to get through by the end of 'twenty five. That may drift into early part of 'twenty six, just depending on how quickly the FDA is processing things at that time. Speaker 200:24:06But, Eki, if you could, just talk a little bit about the key milestones that you have in front of us, Qsub and then what you guys are doing from a product development point of view and where you hope to be kind of going into next year? Speaker 600:24:21All right. Thank you, Josh. So our QSAT is planned like that's in 6 to 8 weeks from now. We are right now putting all the material together. I would say we are 50% there. Speaker 600:24:34We are going to start, I would say, the revision process next week. So we are all going into that and revise it by all the needs. And it's a pretty formalized process, where you are just presenting your intended use, you're presenting the method or the assay. And you are presenting what kinds of studies like analytical validation, clinical validation you're planning. And then you ask the FDA question, are you fine with that? Speaker 600:25:16Is our analytical validation recording what you are looking for is our clinical validation recording what you are looking for. And then we hope to get good answers. We had made actually pretty good experience with the FDA when we did our BDD submission last year. They are very cooperative. And so they are really trying to work with you and not against you, which I really appreciated. Speaker 600:25:50So bottom line that there is some time to tell us, okay, this is okay, this might be perhaps this or that detail, something where we want to have a modification, which at the end of the day helps us for the design and planning of our IVD endeavor. That said, also the IVD route is a very, very formalized way of putting documents and data together. It starts with Phase 1, which is design spending and inputs. So you are completely put together how your design should look like and have all the inputs in there like, okay, what are we going to achieve? What is our target? Speaker 600:26:47And that's something we want to get finalized by in actually 6 weeks from now. So we want to have that phase done in 6 weeks. And from there, you are getting into the 2nd phase, which is development and design output. So from there, you are developing everything like work packages, what you want to do, how you want to do that, which study and so forth. And then the design output, it means you are controlling that what you have put into your design document really can be achieved. Speaker 600:27:26So that's the second so called phase gate. And then the 3rd phase is verification and validation. That's where we are going to do an analytical validation and physical validation with the at that point locked in final product. And this we are have planned to get accomplished by Q4 20 fivetwenty 26. So that's the entire plan. Speaker 600:27:59It's a lot of writing documents and just show the FDA that you are have thought about everything that needed to be thought about and that you are not just getting some data randomly put together by chance. The entire idea behind that is starting with the so called design control. Everything needs to be set from the very beginning and then you are just working along what you have planned. Speaker 200:28:33Perfect. Understood. Thank you, Aki. Operator00:28:36And then I Speaker 200:28:37just want to make one comment on I just want to make one quick comment. Just one quick comment. Yes. One thing that we've been pleasantly surprised with is kind of the warm reception to the IVD program we felt from the community. One of the questions we're asking these sites as we're bringing them up and we're moving them through the funnel is, hey, are you interested in participating in the IVD program? Speaker 200:28:59And it's just kind of been overwhelmingly positive. I think these centers want to help us get the samples together. They want to help us with the reproducibility studies. And so it's really feeling like a community effort here to push the IVD process along. So I think we're overwhelmed by the positive support that we're getting from the community. Speaker 200:29:21And I think there's just a general excitement that they're going to have access to this technology, and they get to help make it happen. Operator00:29:31There are no further questions from the line at this time. I'd like to ask Jeff to see if we have any questions from the webcast. Speaker 100:29:41Yes, we do have a few actually. Thank you. Josh, Andrea, how do you calculate the $1,000,000,000 transplant testing market opportunity? And how does OncoCyte plan to capture its $1,000,000,000 market opportunity? Speaker 200:29:57I mean, it's a good question. I think we put this out, I think, in our investor deck. But we've got an estimate of somewhere around 3,000,000 to 3,500,000 testing opportunities globally. And that number, we're obviously multiplying that by a mix of our RUO product and our IVD product, where we expect to be IVD in the U. S. Speaker 200:30:18And Europe and then probably say RUO Rest of World. That market is growing, at least according to current estimates about 9% a year. So we see the $1,000,000,000 as a relatively conservative estimate of what the market opportunity is. And we're not going to move that up until we have a chance to do more price discovery. And so it's just something that's hard to do until, let's say, you actually have the IVD product out there and know what you're going to get reimbursed. Speaker 200:30:46So we're erring on the side of being conservative there. From a market capture point of view, I think we've talked about this a good bit, but it's democratization, right? It's giving people access, and it's meeting the demand where it is, which, you know, right now, the demand is at the local center, and they don't have access to a technology that works for them today. Speaker 300:31:11Do you want to add just a little bit about that $1,000,000,000 total addressable market is based on the current clinical indication? Speaker 200:31:20Yes. I mean, I think the most exciting thing for us that's come out of the past 2 or 3 months is the work that's being done on like the anti CD38 drugs where they're really meeting an unmet clinical need from a pharma point of view. And that just opens up kind of just these significant monitoring opportunities. So therapeutic efficacy monitoring, like is the drug working, then also recurrence monitoring. And we're seeing a lot of this in oncology right now. Speaker 200:31:53And there's just an enormous amount of value creation that's happening in the oncology space, just kind of like on that therapeutic efficacy and recurrence monitoring. And we're starting to see that emerge here in transplant. And so we're we've got our fingers crossed that these trials will continue to be successful, so that patients have an option instead of just losing their organ. And I think that creates that's an incredible tailwind for us because we're out in front there. And so I would say that easily expands the market opportunity that's in front of us. Speaker 400:32:33Very good. Speaker 600:32:36If I may, I would just add to what TOS was saying to make it really clear what the new situation that we have created is. I recall a net board meeting like perhaps 8 months ago, where we were talking how much would you use the test in a high risk population. And most of the people are saying, why should I? We don't have any therapy. Why do I want to know? Speaker 600:33:04And this has dramatically changed. Now we have the first working therapy for chronic active antibody mediated rejection. And it's not only something where we can show our test is perfect monitoring. It's also a huge, huge relief for patients who are suffering, Because earlier than that, there was no therapeutic option. And the organ would ultimately be lost, and now we have a therapeutic option. Speaker 600:33:37And our contribution is really to show that people are going into this disease earlier, then we can do it with standard of care. And Speaker 200:34:00Great. Thank you, Akhi. Speaker 100:34:04I have one other question, Josh. Speaker 200:34:07Okay. Speaker 100:34:07How does OncoCyte envision building recurring revenue streams when most diagnostics currently are performed episodically. That wasn't even as bad as before. Sorry. Speaker 200:34:20Yes. I would say the transplant is inherently a recurring revenue opportunity because patients are living with their organs hopefully for 10, 12, 15 years or better. And unfortunately though, there's a high rate of rejection. And so there's just inherently a number of touch points over the life of the patient. The physician just needs a non invasive way or a minimally invasive way to check on that organ. Speaker 200:34:56And we along with the other players in the space are kind of meeting that need. And so I think it's just inherent to the product and the industry that we're in. Speaker 100:35:11Got it. Okay, great. There's no more questions. Rochelle? Operator00:35:18Currently, we don't have any questions from the line. Speaker 300:35:32Thanks, Rachelle and Jeff. I guess we'll give it maybe like 5 seconds here, pregnant applause, and then maybe Josh will close this out. Speaker 200:35:44Okay, guys. Thanks everybody for joining us today. I mean, we're obviously excited about where we're at as a company. It feels great to be out in the field with the product engaging with the research community and just feeling a groundswell of support. So we look forward to updating you guys on our progress and capturing these sites across the United States and across Europe. Speaker 200:36:09We'll have some very exciting things to announce here in the future and thanks for playing along. Operator00:36:16Thank you. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by